In a phase 3 trial of Ocrevus (ocrelizumab), Roche Group’s Genentech saw its twice-yearly subcutaneous injection meet primary and secondary endpoints in patients with relapsing forms of MS or primary progressive MS, according to a news release.
The investigative subcutaneous therapy had similar safety and efficacy results as its approved intravenous solution, according to Genentech.
“Detailed results from the trial will be presented at an upcoming medical meeting and submitted to health authorities around the world,” the company said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
